Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential

기사 요약

Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.